Tech Company Financing Transactions
Shoreline Biosciences Funding Round
Shoreline Biosciences, based in San Diego, raised $43 million from Boxer Capital, BVF Partners and Commodore Capital.
Transaction Overview
Company Name
Announced On
4/9/2021
Transaction Type
Venture Equity
Amount
$43,000,000
Round
Undisclosed
Investors
Boxer Capital (Lead Investor) (Christopher Fuglesang)
Proceeds Purpose
The company intends to use the funds to accelerate the advancement of its proprietary iPSC platform focused on developing next generation NK cell and macrophage-cell therapies, while also supporting research efforts to create potent and persistent NK cell-specific Chimeric Antigen Receptors (CARs), switchable CAR-NK cell engagers and macrophage-specific CARs.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
11408 Sorrento Valley Rd.
San Diego, CA 92121
USA
San Diego, CA 92121
USA
Phone
Undisclosed
Website
Email Address
Overview
To establish safe, effective, and affordable cell-based immunotherapies for the treatment of seriously ill patients. Through innovative thinking and tenacity we strive to discover and develop clinically effective immunotherapies using intelligently engineered iPSC-derived allogeneic cells to save lives.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Kleanthis Xanthopoulos
Co-Founder
Steven Holtzman
Co-Founder
Daniel Kaufman
Co-Founder
William Sandborn
Browse more venture capital transactions:
Prev: 4/9/2021: Ramp Financial venture capital transaction
Next: 4/9/2021: Elevate Brands venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to record every notable VC transaction. VC investment data records reported here are derived from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs